HOOKIPA Pharma Inc. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| Peters Malte | Chief Executive Officer | Sale | 25,172 | $0.82 | $20,641 | 54,347 | Aug 19, 2025 |
| Peters Malte | Chief Executive Officer | Sale | 29,176 | $0.92 | $26,842 | 79,519 | Jul 22, 2025 |
| Coelho Mary Theresa | EVP and CFO | Sale | 13,609 | $0.92 | $12,520 | 56,266 | Jul 22, 2025 |
| Coelho Mary Theresa | EVP and CFO | Award / Grant | 69,875 | — | — | 69,875 | Jul 22, 2024 |
| Peters Malte | Chief Executive Officer | Award / Grant | 108,695 | — | — | 108,695 | Jul 22, 2024 |
| Kandera Reinhard | Chief Financial Officer | Purchase | 7,000 | $0.73 | $5,110 | 43,092 | Aug 21, 2023 |
| Kandera Reinhard | Chief Financial Officer | Purchase | 8,000 | $0.71 | $5,680 | 36,092 | Aug 16, 2023 |
| Aldag Jorn | Chief Executive Officer | Purchase | 5,000 | $0.83 | $4,150 | 71,952 | Jul 7, 2023 |
| Aldag Jorn | Chief Executive Officer | Purchase | 5,000 | $0.89 | $4,450 | 61,952 | Jul 5, 2023 |
| Aldag Jorn | Chief Executive Officer | Purchase | 5,000 | $0.89 | $4,450 | 56,952 | Jul 3, 2023 |
| Kandera Reinhard | Chief Financial Officer | Purchase | 12,000 | $0.88 | $10,560 | 28,092 | Jun 30, 2023 |
| Orlinger Klaus | Executive VP, Research | Award / Grant | 9,188 | $3.00 | $27,564 | 10,404 | Feb 1, 2022 |
| Baker Christine D. | Chief Business Officer | Award / Grant | 13,658 | $3.00 | $40,974 | 16,158 | Feb 1, 2022 |
| Necina Roman | Chief Technology Officer | Award / Grant | 12,892 | $3.00 | $38,676 | 14,876 | Feb 1, 2022 |
| Matushansky Igor | Chief Medical Officer | Award / Grant | 14,933 | $3.00 | $44,799 | 100,240 | Feb 1, 2022 |
| Kandera Reinhard | Chief Financial Officer | Award / Grant | 14,056 | $3.00 | $42,168 | 16,092 | Feb 1, 2022 |
| Aldag Jorn | Chief Executive Officer | Award / Grant | 47,824 | $3.00 | $143,472 | 51,952 | Feb 1, 2022 |
| Matushansky Igor | Chief Medical Officer | Sale | 2,205 | $2.49 | $5,490 | 85,307 | Dec 21, 2021 |
| Sofinnova Partners SAS | — | Sale | 328,620 | $11.60 | $3,811,992 | 3,177,574 | Apr 21, 2021 |
| SOFINNOVA CAPITAL VI FCPR | — | Sale | 36,829 | $13.67 | $503,452 | 3,506,194 | Mar 29, 2021 |
| Sofinnova Partners SAS | — | Sale | 35,171 | $13.69 | $481,491 | 3,543,023 | Mar 26, 2021 |
| Sofinnova Partners SAS | — | Sale | 28,546 | $13.12 | $374,524 | 3,578,194 | Mar 25, 2021 |
| Sofinnova Partners SAS | — | Sale | 52,690 | $13.70 | $721,853 | 3,606,740 | Mar 24, 2021 |
| Sofinnova Partners SAS | — | Sale | 40,000 | $13.91 | $556,400 | 3,659,430 | Mar 23, 2021 |
| SOFINNOVA CAPITAL VI FCPR | — | Sale | 40,534 | $14.54 | $589,364 | 3,699,430 | Mar 22, 2021 |
| Sofinnova Partners SAS | — | Sale | 166,230 | $14.60 | $2,426,958 | 3,739,964 | Mar 19, 2021 |
| Matushansky Igor | Chief Medical Officer | Option Exercise | 29,628 | $0.10 | $2,963 | 93,881 | Dec 17, 2020 |
| van de Winkel Jan | — | Award / Grant | 9,153 | — | — | 9,153 | Oct 21, 2020 |
| Kelly Michael Aaron | — | Award / Grant | 5,754 | — | — | 5,754 | Oct 21, 2020 |
| Kaufman David Ross | — | Award / Grant | 4,577 | — | — | 4,577 | Oct 21, 2020 |
| Lengauer Christoph | — | Award / Grant | 4,603 | — | — | 4,603 | Oct 21, 2020 |
| O'Neill Julie | — | Award / Grant | 4,969 | — | — | 4,969 | Oct 21, 2020 |
| van Deventer Sander | — | Award / Grant | 2,485 | — | — | 2,485 | Oct 21, 2020 |
| Seghezzi Graziano | — | Award / Grant | 4,708 | — | — | 4,708 | Oct 21, 2020 |
| Sofinnova Partners SAS | — | Sale | 300 | $10.00 | $3,000 | 3,906,194 | Oct 2, 2020 |
| SOFINNOVA CAPITAL VI FCPR | — | Sale | 32,336 | $12.45 | $402,583 | 3,915,755 | Sep 15, 2020 |
| SOFINNOVA CAPITAL VI FCPR | — | Sale | 12,483 | $11.94 | $149,047 | 3,948,091 | Jul 20, 2020 |
| Necina Roman | Chief Technology Officer | Award / Grant | 1,984 | — | — | 1,984 | Jul 20, 2020 |
| Orlinger Klaus | EVP, Research | Award / Grant | 1,216 | — | — | 1,216 | Jul 20, 2020 |
| Kandera Reinhard | Chief Financial Officer | Award / Grant | 2,036 | — | — | 2,036 | Jul 20, 2020 |
| Matushansky Igor | Chief Medical Officer | Award / Grant | 2,736 | — | — | 56,134 | Jul 20, 2020 |
| Aldag Jorn | Chief Executive Officer | Award / Grant | 4,128 | — | — | 4,128 | Jul 20, 2020 |
| Sofinnova Partners SAS | — | Sale | 3,280 | $11.78 | $38,638 | 3,960,574 | Jun 29, 2020 |
| SOFINNOVA CAPITAL VI FCPR | — | Sale | 3,280 | $11.78 | $38,638 | 3,960,574 | Jun 29, 2020 |
| SOFINNOVA CAPITAL VI FCPR | — | Sale | 3,280 | $11.78 | $38,638 | 3,960,574 | Jun 29, 2020 |
| Matushansky Igor | Chief Medical Officer | Sale | 5,500 | $12.73 | $70,015 | 53,398 | Jan 29, 2020 |
| Lilja Anders | Sr. VP, Technical Development | Sale | 7,568 | $12.81 | $96,946 | — | Jan 23, 2020 |
| Orlinger Klaus | Sr. VP, Research | Sale | 1,711 | $11.56 | $19,779 | — | Jan 16, 2020 |
| Orlinger Klaus | Sr. VP, Research | Sale | 8,500 | $11.30 | $96,050 | — | Jan 14, 2020 |
| Matushansky Igor | Chief Medical Officer | Option Exercise | 6,000 | $0.10 | $600 | 49,411 | Dec 19, 2019 |